ELI LILLY & Co is 570.3x more valuable than Sarepta Therapeutics, Inc. by market capitalization ($1.072 T vs $1.88 B). Every figure below comes from audited SEC filings and refreshed market data.
| Metric | SRPT | LLY |
|---|---|---|
| Market cap | $1.88 B | $1.072 T |
| US-listed rank | #2138 | #10 |
| Revenue (latest FY) | $1.86B | $65.18B |
| Net income (latest FY) | -$713.41M | $20.64B |
| Net margin | -38.3% | 31.7% |
| P/E (trailing FY) | - | 51.9 |
| SEC filings | 1,504 | 989 |
ELI LILLY & Co is 570.3x more valuable than Sarepta Therapeutics, Inc. by market capitalization ($1.072 T vs $1.88 B).
In their latest fiscal years, Sarepta Therapeutics, Inc. reported $1.86B in revenue while ELI LILLY & Co reported $65.18B.
Full pages: Sarepta Therapeutics, Inc. and ELI LILLY & Co, or browse the full rankings.